title: Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Richardson
authors.forename: Karen S
authors.initials: KS
authors.lastname: McGinnis
authors.forename: Michael
authors.initials: M
authors.lastname: Shapiro
authors.forename: Michael S
authors.initials: MS
authors.lastname: Lehrer
authors.forename: Ellen J
authors.initials: EJ
authors.lastname: Kim
authors.forename: Carmela C
authors.initials: CC
authors.lastname: Vittorio
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Junkins Hopkins
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077610:Bexarotene; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D017893:Photopheresis; D012751:Sezary Syndrome / Q000628:therapy; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene